scholarly journals P-346 Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real life: The CASSIOPEE Study - Interim analysis on patients' characteristics

2015 ◽  
Vol 26 ◽  
pp. iv100 ◽  
Author(s):  
E. François ◽  
S. Kim ◽  
G. Deplanque ◽  
D. Smith ◽  
S. Gourgou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Interim Analysis ◽  
Real Life ◽  
First Line ◽  
Interventional Study

scholarly journals Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

2010 ◽  
Vol 102 (10) ◽  
pp. 1468-1473 ◽  
Author(s):  
J Feliu ◽  
M J Safont ◽  
A Salud ◽  
F Losa ◽  
C García-Girón ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Cetuximab with irinotecan or oxaliplatin for first-line metastatic colorectal cancer: Effectiveness in the EREBUS cohort compared to pivotal trials.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14542-e14542
Author(s):  
Annie Fourrier-Réglat ◽  
Magali Rouyer ◽  
Pernelle Noize ◽  
Emmanuelle Bignon ◽  
Alise Le Monies ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Treatment Initiation ◽  
Response Rate ◽  
Real Life ◽  
Wild Type ◽  
First Line ◽  
Multicenter Cohort Study ◽  
Baseline Characteristics ◽  
One Year

e14542 Background: Cetuximab (CTX) has demonstrated improved survival outcomes in metastatic colorectal cancer (mCRC) but information from real-life use is sparse. Here, CTX survival and safety outcomes in real-life are compared to those observed in OPUS and CRYSTAL trials. Methods: EREBUS is a French multicenter cohort study that included over two years (2009-2010) patients with unresectable mCRC and wild-type KRAS initiating CTX as 1st-line therapy in 65 centres and followed for 12 months from treatment initiation. Results: We included 389 patients treated with a combination of CTX with irinotecan-based (56.0%) or CTX with oxaliplatin-based (37.8%) chemotherapy. The main characteristics, safety, response rate, and one year survival of this cohort are presented in the Table below in parallel with results obtained in pivotal trials. Conclusions: Despite differences in baseline characteristics between real-life and pivotal trials (such as ECOG status), the response rate and PFS were comparable in mCRC patients with wt KRAS treated with 1st-line CTX. The nature of adverse events was in-line with the trials but the frequency was lower probably owing to under-notification in real-life. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document